Stockscreener 앱 받기
12.76
1.69%
-0.22
시간 외 거래:
12.76
전일 마감가:
$12.98
열려 있는:
$12.92
하루 거래량:
149.30K
Relative Volume:
0.54
시가총액:
$341.66M
수익:
$31.38M
순이익/손실:
$-6.69M
주가수익비율:
-49.08
EPS:
-0.26
순현금흐름:
$-1.84M
1주 성능:
-7.13%
1개월 성능:
-18.73%
6개월 성능:
+115.91%
1년 성능:
+240.27%
1일 변동 폭
$12.52
$13.16
1주일 범위
$12.24
$14.31
52주 변동 폭
$3.03
$18.41
Eton Pharmaceuticals Inc Stock (ETON) Company Profile
명칭
Eton Pharmaceuticals Inc
전화
(847) 787-7361
주소
21925 W. FIELD PARKWAY, DEER PARK, IL
ETON을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ETON
Eton Pharmaceuticals Inc
|
12.76 | 341.66M | 31.38M | -6.69M | -1.84M | -0.26 |
|
ZTS
Zoetis Inc
|
161.91 | 72.51B | 9.26B | 2.49B | 2.30B | 5.47 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.90 | 47.09B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
10.18 | 46.06B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
15.29 | 17.47B | 16.54B | -1.64B | 749.00M | -1.45 |
|
ITCI
Intra Cellular Therapies Inc
|
131.87 | 14.06B | 612.78M | -86.37M | -62.91M | -0.87 |
Eton Pharmaceuticals Inc Stock (ETON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-01-23 | 재확인 | H.C. Wainwright | Buy |
| 2025-01-10 | 개시 | B. Riley Securities | Buy |
| 2025-01-06 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-04 | 재개 | H.C. Wainwright | Buy |
| 2024-05-06 | 개시 | Craig Hallum | Buy |
| 2021-10-14 | 재개 | B. Riley Securities | Buy |
| 2021-01-04 | 재확인 | H.C. Wainwright | Buy |
| 2019-09-20 | 개시 | B. Riley FBR | Buy |
| 2019-06-10 | 개시 | H.C. Wainwright | Buy |
모두보기
Eton Pharmaceuticals Inc 주식(ETON)의 최신 뉴스
Eton sells ex-U.S. rights for hormone disorder therapy to Esteve Pharma - MSN
Eton sells overseas rights for hormone disorder drug (ETON) - Seeking Alpha
Eton Pharma Out-Licenses International Rights To Increlex To Esteve Pharma - Nasdaq
Eton Pharmaceuticals out-licenses international rights to Increlex - TipRanks
Eton Pharmaceuticals IncEsteve To Pay Eur4 Million Up Front For Increlex RightsSEC Filing - MarketScreener
Eton Pharmaceuticals licenses Increlex rights abroad - Investing.com
Eton Pharmaceuticals Out-Licenses International Rights to Increlex® - GlobeNewswire
Eton Pharmaceuticals Inc (ETON) Shares Down 4.87% on Mar 25 - GuruFocus
CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - The Manila Times
REG-CROSSJECT updates on its collaboration with ETON PHARMACEUTICALS, Inc. and the ZENEO® adrenal insufficiency program - TradingView
Q3 EPS Estimates for Eton Pharmaceuticals Lifted by B. Riley - Defense World
Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright - Defense World
Eton Pharmaceuticals Inc (ETON) Stock Price Down 3.79% on Mar 22 - GuruFocus
Research Analysts Set Expectations for ETON Q2 Earnings - Defense World
B. Riley Reiterates Buy Rating for Eton Pharmaceuticals (NASDAQ:ETON) - Defense World
Eton Pharmaceuticals (NASDAQ:ETON) Stock Price Expected to Rise, Craig Hallum Analyst Says - Defense World
Q1 EPS Forecast for Eton Pharmaceuticals Boosted by Analyst - Defense World
5 Analysts Assess Eton Pharmaceuticals: What You Need To Know - Benzinga
Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Q4 2024 Earnings Call Transcript - Insider Monkey
B. Riley Raises Price Target on Eton Pharmaceuticals to $24 From $21, Keeps Buy Rating - MarketScreener
Eton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags - Yahoo Finance
Eton Pharmaceuticals Reports Record Q4 Revenue Growth - TipRanks
Eton Pharmaceuticals Reports Strong Growth and Strategic Acquisitions - TipRanks
Eton Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results - TradingView
Eton Pharmaceuticals Reports Record Q4 2024 Revenue and Successful Product Launches Ahead of Investor Day Conference Call - Nasdaq
Eton Pharmaceuticals Achieves 16th Straight Quarter of Growth, Doubles Product Portfolio - StockTitan
Earnings Scheduled For March 18, 2025 - Benzinga
Eton Pharmaceuticals (NASDAQ:ETON) shareholder returns have been incredible, earning 421% in 5 years - Simply Wall St
(ETON) On The My Stocks Page - news.stocktradersdaily.com
Eton Pharmaceuticals nears NDA submission for new drug By Investing.com - Investing.com Australia
Eton Pharma Plans FDA Filing For ET-600 Oral Desmopressin Next Month, Eyes 2026 Launch - Benzinga India
Eton Pharma rises on study results for rare disease drug - TradingView
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Eton's Diabetes Drug Candidate Passes Bioequivalence Study -March 14, 2025 at 07:21 am EDT - Marketscreener.com
Eton Pharmaceuticals nears NDA submission for new drug - Investing.com India
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600 - Eagle-Tribune
Breakthrough for Pediatric Diabetes: Eton's Liquid Desmopressin Aces Pivotal Trial - StockTitan
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga India
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Eton Pharmaceuticals (ETON) to Release Earnings on Thursday - Defense World
Trading (ETON) With Integrated Risk Controls - news.stocktradersdaily.com
Optime Care Partners with Eton Pharmaceuticals as a Specialty Pharmacy Provider for GALZIN® - The Manila Times
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025 - GlobeNewswire
How Will Eton's Rare Disease Acquisitions Impact Future Growth? Investor Day Set to Reveal Strategy - StockTitan
Eton Pharmaceuticals Launches Galzin Capsules for Wilson Disease Treatment -March 03, 2025 at 11:48 am EST - Marketscreener.com
Eton Pharmaceuticals launches FDA-approved Wilson disease treatment - Investing.com
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules - GlobeNewswire
Only FDA-Approved Zinc Treatment for Wilson Disease Now AvailableWhat Makes Galzin Different? - StockTitan
60,432 Shares in Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Acquired by Anchor Capital Advisors LLC - MarketBeat
Eton Pharmaceuticals Inc (ETON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.48%
0.34%
자본화:
|
볼륨(24시간):